Next Article in Journal
MicroRNAs as Biomarkers in Colorectal Cancer
Next Article in Special Issue
The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis
Previous Article in Journal
Anaplastic Lymphoma Kinase in Cutaneous Malignancies
Previous Article in Special Issue
Stem Cell-Like Properties of CK2β-down Regulated Mammary Cells
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2017, 9(9), 122; https://doi.org/10.3390/cancers9090122

EMT and Treatment Resistance in Pancreatic Cancer

1
Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Department of Medicine, University of Verona, Verona 37134, Italy
2
Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona 37134, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Joëlle Roche
Received: 27 July 2017 / Revised: 1 September 2017 / Accepted: 10 September 2017 / Published: 12 September 2017
(This article belongs to the Special Issue The Epithelial-to-Mesenchymal Transition (EMT) in Cancer)
View Full-Text   |   Download PDF [672 KB, uploaded 12 September 2017]   |  

Abstract

Pancreatic cancer (PC) is the third leading cause of adult cancer mortality in the United States. The poor prognosis for patients with PC is mainly due to its aggressive course, the limited efficacy of active systemic treatments, and a metastatic behavior, demonstrated throughout the evolution of the disease. On average, 80% of patients with PC are diagnosed with metastatic disease, and the half of those who undergo surgery and adjuvant therapy develop liver metastasis within two years. Metastatic dissemination is an early event in PC and is mainly attributed to an evolutionary biological process called epithelial-to-mesenchymal transition (EMT). This innate mechanism could have a dual role during embryonic growth and organ differentiation, and in cancer progression, cancer stem cell intravasation, and metastasis settlement. Many of the molecular pathways decisive in EMT progression have been already unraveled, but little is known about the causes behind the induction of this mechanism. EMT is one of the most distinctive and critical features of PC, occurring even in the very first stages of tumor development. This is known as pancreatic intraepithelial neoplasia (PanIN) and leads to early dissemination, drug resistance, and unfavorable prognosis and survival. The intention of this review is to shed new light on the critical role assumed by EMT during PC progression, with a particular focus on its role in PC resistance. View Full-Text
Keywords: pancreatic cancer; EMT; resistance pancreatic cancer; EMT; resistance
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Gaianigo, N.; Melisi, D.; Carbone, C. EMT and Treatment Resistance in Pancreatic Cancer. Cancers 2017, 9, 122.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top